Sigma Planning Corp Has $2.63 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Sigma Planning Corp raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 3.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,564 shares of the life sciences company’s stock after purchasing an additional 166 shares during the quarter. Sigma Planning Corp’s holdings in Illumina were worth $2,633,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Neuberger Berman Group LLC lifted its stake in shares of Illumina by 16.0% in the 2nd quarter. Neuberger Berman Group LLC now owns 56,958 shares of the life sciences company’s stock valued at $26,547,000 after acquiring an additional 7,871 shares during the last quarter. Dai Ichi Life Insurance Company Ltd lifted its stake in shares of Illumina by 123.6% in the 2nd quarter. Dai Ichi Life Insurance Company Ltd now owns 10,854 shares of the life sciences company’s stock valued at $5,136,000 after acquiring an additional 6,000 shares during the last quarter. LPL Financial LLC lifted its stake in shares of Illumina by 9.9% in the 2nd quarter. LPL Financial LLC now owns 27,270 shares of the life sciences company’s stock valued at $12,904,000 after acquiring an additional 2,456 shares during the last quarter. Philadelphia Trust Co. lifted its stake in shares of Illumina by 0.5% in the 2nd quarter. Philadelphia Trust Co. now owns 15,005 shares of the life sciences company’s stock valued at $7,101,000 after acquiring an additional 70 shares during the last quarter. Finally, Bridgewater Associates LP bought a new position in shares of Illumina in the 2nd quarter valued at $5,187,000. Institutional investors own 88.56% of the company’s stock.

In other Illumina news, SVP Charles Dadswell sold 314 shares of Illumina stock in a transaction dated Wednesday, September 22nd. The stock was sold at an average price of $436.69, for a total transaction of $137,120.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Susan H. Tousi sold 100 shares of Illumina stock in a transaction dated Tuesday, September 28th. The shares were sold at an average price of $418.04, for a total value of $41,804.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,642 shares of company stock valued at $1,268,895 in the last quarter. Company insiders own 0.23% of the company’s stock.

A number of brokerages have recently commented on ILMN. TheStreet cut Illumina from a “b-” rating to a “c” rating in a research note on Wednesday, October 6th. SVB Leerink lowered Illumina from an “outperform” rating to a “market perform” rating and set a $425.00 target price for the company. in a research report on Thursday, August 19th. Canaccord Genuity raised their target price on Illumina from $515.00 to $555.00 and gave the stock a “buy” rating in a research report on Monday, August 9th. Barclays raised their target price on Illumina from $355.00 to $365.00 and gave the stock an “underweight” rating in a research report on Friday, August 6th. Finally, Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $504.00 target price for the company in a research report on Wednesday, June 30th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $432.83.

Shares of ILMN opened at $405.14 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 6.08 and a quick ratio of 5.64. The stock has a 50-day moving average of $454.67 and a 200-day moving average of $439.18. The company has a market cap of $59.43 billion, a PE ratio of 77.61, a P/E/G ratio of 2.24 and a beta of 0.91. Illumina, Inc. has a one year low of $288.01 and a one year high of $555.77.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, August 5th. The life sciences company reported $1.87 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.36 by $0.51. The company had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.01 billion. Illumina had a return on equity of 18.12% and a net margin of 19.36%. During the same period last year, the business posted $0.62 EPS. Analysts expect that Illumina, Inc. will post 6.48 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.

Featured Story: What is a stock portfolio tracker?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.